Total buying$1.68M2 buys
XENE
Xenon Pharmaceuticals Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$00 sells
Net open-market+$1.68MBuying minus selling
Active insiders2Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 17, 2026
Open-market transaction mix · 2 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 2 | 0 | 0 | $1.68M | $0 | $1.68M |
| Oct 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (2)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- MI+$1.1M
- KP—
XENE transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
XENEXenon Pharmaceuticals Inc. | Kelly Thomas PatrickCFO | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
XENEXenon Pharmaceuticals Inc. | Kelly Thomas PatrickCFO | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
XENEXenon Pharmaceuticals Inc. | Kelly Thomas PatrickCFO | P · buySEC filing ↗ | $559kView disclosure → | |
XENEXenon Pharmaceuticals Inc. | Mortimer IanPRES · CEO | P · buySEC filing ↗ | $1.12MView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Recent filing activity
Most recent 4 transactions on this page · color = transaction codeFiling detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period4transactionstxns
- M · Option exercise · dominant2 · 50%
- P · Open-market buys2 · 50%
Activity by reported role
A joint filing can contribute to multiple rolesChief financial officer3
Chief executive officer1
PRES1
Reported Holdings After
Separated by insider, security, and ownership type
Kelly Thomas PatrickCommon Shares · Direct
22,500Oct 15, 2026
Mortimer IanCommon Shares · Direct
49,923Sep 30, 2026
Kelly Thomas PatrickRestricted Share Units · Direct
22,500Oct 15, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Xenon Pharmaceuticals Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Xenon Pharmaceuticals Inc.?
Kelly Thomas Patrick, MORTIMER IAN.
When was the latest reported open-market purchase?
Kelly Thomas Patrick reported a buy on Sep 30, 2026 valued at $559k. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $1,681,140.00. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.